标靶治疗市场规模、份额和成长分析（按类型、应用、分销管道和地区）- 产业预测 2025-2032

2023 年全球标靶治疗市场规模价值 732 亿美元，预计将从 2024 年的 752.5 亿美元成长到 2032 年的 938.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 2.8%。

由于单株抗体日益普及和生物技术的投资的增加，全球生技药品和标靶治疗市场正在快速成长。这些标靶治疗可有效抑制癌细胞增殖，并被定位为肿瘤学的主要治疗药物。网上药局的成长预计将促进这些治疗药物的销售。此外，政府加大对医疗基础建设的财政支持力度预计也将为市场扩张做出巨大贡献。到2040年，全球需要针对性治疗的病例数预计将达到2,840万人。此外，大众对可用治疗方法的认识不断提高也推动了市场的成长。然而，挑战仍然存在，因为标靶治疗相关的副作用可能会阻碍市场的整体进步。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

标靶治疗药物市场规模（按类型和复合年增长率） (2025-2032)

• 市场概况
• 单株抗体
  • 血管新生抑制剂
  • HER-2标靶药物
  • 抗CD20单株抗体
• 小分子
  • 蛋白酪氨酸激酶抑制剂
  • mTOR 抑制剂
  • PARP 抑制剂

标靶治疗药物市场规模（依应用划分）及复合年增长率（2025-2032）

• 市场概况
• 乳癌
• 大肠直肠癌
• 白血病
• 肺癌
• 淋巴瘤
• 多发性硬化症
• 肾癌
• 湿性老龄化黄斑部病变
• 其他（卵巢癌、输卵管癌、摄护腺癌、胰臟癌）

标靶治疗药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局

标靶治疗药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Roche（Switzerland）
• Novartis（Switzerland）
• Pfizer（USA）
• Merck & Co.（USA）
• Bristol-Myers Squibb（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Sanofi（France）
• Bayer（Germany）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie（USA）
• Takeda Pharmaceutical（Japan）
• Gilead Sciences（USA）
• Biogen（USA）
• Regeneron Pharmaceuticals（USA）
• Celgene（USA）（Acquired by Bristol-Myers Squibb）
• Incyte（USA）

结论和建议

Global Targeted Therapeutics Market size was valued at USD 73.2 billion in 2023 and is poised to grow from USD 75.25 billion in 2024 to USD 93.85 billion by 2032, growing at a CAGR of 2.8% during the forecast period (2025-2032).

The global market for biologics and targeted therapeutics is experiencing rapid growth, driven by the increasing popularity of monoclonal antibodies and rising investments in biotechnology. These targeted therapies effectively inhibit tumor cell proliferation, positioning them as leading treatments in oncology. Anticipated growth in online pharmacies is expected to enhance the sales of these therapeutic drugs. Additionally, heightened government financial support aimed at advancing healthcare infrastructure will significantly contribute to market expansion. By 2040, global cases of targeted therapeutic needs are projected to reach 28.4 million. Furthermore, growing awareness among the population about available treatments is also propelling market growth. However, challenges remain, as side effects related to targeted therapies could hinder overall market progress.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Therapeutics Market Segments Analysis

Global Targeted Therapeutics Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Monoclonal Antibodies and Small Molecule. Based on Application, the market is segmented into Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, Renal Cancer, Wet Age-related Macular Degeneration and Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer). Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Targeted Therapeutics Market

The Global Targeted Therapeutics market is primarily driven by the rising incidence of cancer coupled with the growing disposable income of individuals. As cancer rates continue to escalate worldwide, there is an increasing demand for innovative treatment options that offer more precise targeting of cancer cells, thus providing better outcomes for patients. Additionally, as disposable incomes rise, more patients are able to afford advanced therapies and medications, fueling the market's growth. This combination of heightened cancer prevalence and improved economic conditions creates a favorable environment for the expansion of targeted therapeutics, ultimately enhancing patient care and treatment accessibility.

Restraints in the Global Targeted Therapeutics Market

The global targeted therapeutics market faces several constraints, particularly related to the side effects associated with targeted therapies and drugs. These adverse effects can vary in severity and may include reactions that impact a patient's quality of life, leading to increased discontinuation rates and reluctance among healthcare providers to prescribe these treatments. Furthermore, the complexity of managing these side effects often requires additional resources, complicating care and potentially driving up healthcare costs. As a result, these challenges can hinder market growth and limit the overall adoption of targeted therapeutics in various therapeutic areas.

Market Trends of the Global Targeted Therapeutics Market

The global targeted therapeutics market is experiencing significant growth, driven by strategic collaborations, acquisition activities, and innovative product launches among major players. Companies are focusing on expansion strategies to enhance their therapeutic offerings, with a notable push in developing complement-targeted therapies to address various diseases. For instance, PubMed Inc.'s release of upgraded therapies showcases a commitment to improving treatment efficacy and addressing complex pathological conditions. This trend indicates a robust pipeline of novel therapies aimed at personalization and precision medicine, positioning the market for sustained growth as demand for tailored treatment options continues to rise globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
  • Angiogenesis Inhibitors
  • HER-2 Targeted Agents
  • Anti-CD20 Monoclonal Antibodies
• Small Molecule
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • PARP Inhibitors

Global Targeted Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-related Macular Degeneration
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)

Global Targeted Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Targeted Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (USA) (Acquired by Bristol-Myers Squibb)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations